{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:04:28Z","timestamp":1780639468443,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2023-26-16"],"award-info":[{"award-number":["320.6750.2023-26-16"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["Z04JKM2023E040"],"award-info":[{"award-number":["Z04JKM2023E040"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Antibiot."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In contemporary clinical practice, novel tetracycline-class antimicrobial agents have been increasingly utilized due to their favorable pharmacological profiles. However, the potential association between novel tetracycline-class drugs and coagulation dysfunction is relatively underreported in the literature. This study utilizes the FDA Adverse Event Reporting System (FAERS) to identify and analyze risk signals for coagulation disorders associated with three commonly used the novel tetracyclines in clinical practice. The findings are expected to provide valuable references for clinicians in the targeted monitoring of adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Coagulation dysfunction reports associated with the novel tetracycline-class drugs, submitted to the FDA Adverse Event Reporting System (FAERS) from January 2004 to December 2024, were collected. Data mining was performed using the ROR, PRR, BCPNN, and MGPS. All data extraction was conducted using R software (version 4.4.2).It should be noted that FAERS is a spontaneous reporting system without exposure denominators and is subject to reporting bias and confounding factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 346 coagulation dysfunction reports with the novel tetracycline-class drugs as suspected drugs were screened, including 327 for tigecycline, 6 for omadacycline, and 13 for eravacycline. Disproportionate reporting signals of coagulation dysfunction were detected for both tigecycline and eravacycline, with tigecycline showing the strongest signal [ROR\u00a0=\u00a046.85 (42.29-51.91)]. Subgroup analyses by age, gender, and dosage revealed a higher proportion of male patients receiving tigecycline and eravacycline. while tigecycline and eravacycline exhibited a stronger disproportionate reporting signal in male patients over 65 years old. Omadacycline showed stronger disproportionate reporting signal at a daily dose of 100 mg. The peak onset time for omadacycline was consistently 9 days. However, all subgroup findings for omadacycline and eravacycline should be interpreted with extreme caution due to the limited number of reports. These observations are considered exploratory rather than confirmatory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Disproportionality analysis identified prominent signals of coagulation dysfunction signals associated with tigecycline and eravacycline. Distinctive reporting patterns of coagulation abnormalities were observed across the three novel tetracyclines, with visible discrepancies in patient age, gender, therapeutic indications, daily dosage, clinical outcomes, and adverse event onset time. Based on the above findings, clinicians should maintain high vigilance against the potential coagulation abnormalities induced by novel tetracyclines, and implement standardized and rational therapeutic drug monitoring during clinical medication practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/frabi.2026.1781902","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:38:01Z","timestamp":1780637881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian analysis based on the FAERS database"],"prefix":"10.3389","volume":"5","author":[{"given":"Hongxin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Liaocheng People\u2032s Hospital","place":["Liaocheng, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongna","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000342451","article-title":"Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: Safety profile and efficacy of tigecycline in different treatment modalities","volume":"58","author":"Bodmannk","year":"2012","journal-title":"Chemotherapy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","article-title":"Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA)","volume":"26","author":"Brown","year":"2003","journal-title":"Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/md.0000000000012467","article-title":"Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens","volume":"97","author":"Chen","year":"2018","journal-title":"Med. (Baltimore)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s11096-020-01072-7","article-title":"Tigecycline-associated hypofibrinogenemia in a real-world setting","volume":"42","author":"David","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00824-23","article-title":"Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes","volume":"67","author":"El Ghali","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1160\/TH12-04-0273","article-title":"Fibrinogen gene regulation","volume":"108","author":"Fish","year":"2012","journal-title":"Thromb. Haemost."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1083\/jcb.101.4.1481","article-title":"The effects of hepatocyte stimulating factor on fibrinogen biosynthesis in hepatocyte monolayers","volume":"101","author":"Fuller","year":"1985","journal-title":"J. Cell Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.cmi.2015.11.004","article-title":"Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement","volume":"22","author":"Guan","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.13407\/j.cnki.jpp.1672-108X.2019.11.006","article-title":"Analysis of 50 cases of severe infection in children under 8 years treated with tigecycline in a children\u2019s hospital","volume":"25","author":"Gui","year":"2019","journal-title":"J. Pediatr. Phar"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a realworld study from FDA Adverse Event Reporting System (FAERS) database","volume":"20","author":"Guo","year":"2022","journal-title":"Thromb. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","article-title":"Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients","volume":"76","author":"Hu","year":"2020","journal-title":"Eur. J. Clin. Phar"},{"key":"B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clinmicnews.2023.04.001","article-title":"Review of novel third-generation tetracyclines: eravacycline, omadacycline, and sarecycline","volume":"45","author":"Kim","year":"2023","journal-title":"Clin. Microbiol. Newsl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/1120009X.2022.2105488","article-title":"Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia","volume":"35","author":"Lei","year":"2023","journal-title":"J. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/978-1-4419-1005-9_100041","article-title":"Active monitoring and risk factor analysis of tigecycline adverse drug reactions in the pediatric population","volume":"31","author":"Li","year":"2025","journal-title":"J. Pediatr. Phar"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.6039\/j.issn.1001-0408","article-title":"Data mining and analysis for ADE signals of three third-generation tetracycline antibiotics","volume":"35","author":"Liang","year":"2024","journal-title":"Chin. Phar"},{"key":"B16","first-page":"46","article-title":"Disproportionality analysis of adverse reaction signals for novel tetracycline antibiotics based on the FDA adverse event reporting system database","volume":"22","author":"Liu","year":"2024","journal-title":"Clin. Med. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/TCRM.S302850","article-title":"Risk factors for tigecycline-associated hypofibrinogenemia","volume":"17","author":"Liu","year":"2021","journal-title":"Ther. Clin. Risk Manag"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1111\/jcmm.13865","article-title":"Inhibition of autophagy enhances the antitumour activity of tigecycline in multiple myeloma","volume":"22","author":"Ma","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, real-world, multicenter experience with omadacycline for mycobacterium abscessus infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B20","volume-title":"Research on the safety of antineoplastic drugs based on trigger and data mining","author":"Pan","year":"2019"},{"key":"B21","first-page":"67","article-title":"CHPS-based active surveillance of tigecycline-induced hypofibrinogenemia","volume":"20","author":"Qian","year":"2023","journal-title":"Chin. J. Ration. Drug Use"},{"key":"B22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.13286\/j.1001-5213.2022.09.08","article-title":"Retroapective analysis of hypofib- rinogenemia induced by tigecycline","volume":"42","author":"Qin","year":"2022","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac591","article-title":"Eravacycline associated hypofibrinogen- emia: A case series of transplant patients with mycobacterium abscessus infections and review of literature","volume":"9","author":"Rausch","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/23744235.2015.1043942","article-title":"Hypofibrinogenemia induced by tigecy -cline: a potentially life-threatening coagulation disorder","volume":"47","author":"Sabanis","year":"2015","journal-title":"Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106344","article-title":"Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenemresistant Gram-negative bacilli","volume":"57","author":"Scudeller","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.13461\/j.cnki.cja.007921","article-title":"Clinical application of tetracycline drugs in children","volume":"50","author":"Shi","year":"2025","journal-title":"Chin. J. Antibiotics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious diseases society of America guidance on the treatment of extendedspectrum \u03b2-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204702","article-title":"Progression of fibrinogen decrease during high dose tigecycline therapy in critically ill patients: a retrospective analysis","volume":"10","author":"Treml","year":"2021","journal-title":"J. Clin. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1046\/j.1365-2141.1996.d01-1731.x","article-title":"Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13","volume":"93","author":"Vasse","year":"1996","journal-title":"Br. J. Haematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2217\/fmb-2016-0100","article-title":"Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections","volume":"11","author":"Villano","year":"2016","journal-title":"Future Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1515\/cclm-2013-0899","article-title":"Serum miR-122 levels are related to coagulation disorders in sepsis patients","volume":"52","author":"Wang","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"B32","first-page":"146","article-title":"Research progress on hepatotoxicity caused by per- and polyfluoroalkyl substances","volume":"8","author":"Wang","year":"2022","journal-title":"Biochem. Eng."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/jcpt.13212","article-title":"Analysis of clinical characteristics of tigecycline- induced acute pancreatitis","volume":"45","author":"Weijin","year":"2020","journal-title":"J. Clin. Phar Ther."},{"key":"B34","first-page":"71","article-title":"Analysis of risk factors for hypofibrinogenemia in patients with severe infection caused by tigecycline","volume":"18","author":"Xv","year":"2024","journal-title":"Chin. J. Mod. Drug Appl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2393276","article-title":"Safety profiles of Tetracyclineclass drugs: a pharmacovigilance analysis of the FAERS database","volume":"4","author":"Zhang","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","first-page":"3119","article-title":"Mining and analysis of omada- cycline related adverse drug reaction signals based on FAERS","volume":"38","author":"Zhang","year":"2023","journal-title":"Drugs Clinic"}],"container-title":["Frontiers in Antibiotics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frabi.2026.1781902\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:38:07Z","timestamp":1780637887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frabi.2026.1781902\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":36,"alternative-id":["10.3389\/frabi.2026.1781902"],"URL":"https:\/\/doi.org\/10.3389\/frabi.2026.1781902","relation":{},"ISSN":["2813-2467"],"issn-type":[{"value":"2813-2467","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1781902"}}